Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by Donniebrasco57on Dec 29, 2019 8:57pm
33 Views
Post# 30499896

RE:RE:Investigation on BrendaCalarco & Therunt!!!

RE:RE:Investigation on BrendaCalarco & Therunt!!!
Donniebrasco57 wrote:
Donniebrasco57 wrote: BRENDACALARCO & THERUNT AND ALL YOUR OTHER ALIAS'S KEEP RUNNING AND NEVER LOOK BACK!!! INVESTIGATION UNDERWAY! FOR MARKET MANIPULATION/DEFAMATION OF CHARACTER/ IMPERSONATION/ FRAUD!! EVERY POST IS BEING TRACKED!!! NO ONE HERE HAS ANY LOSSES! ONLY YOU BASHERS ARE RUNNING SCARED!!! YOU CAN TELL BY ALL YOUR PHONEY BALONEY YOU ARE POSTING!!! No Flamer here! I know who I am!!! Obviously you have no idea of what & whom you are, hiding behind different usernames you make up everday! And I doubt you have any shares, the way you are bashing this stock day and night. You must have sold your whole 5 shares that you could have owned once upon a time and lost your lunch money, that's why your bitter and envious of others that have held long. We are all holding strong & long! No matter how much you bash! Keep doing so, you are being tracked!!! They are going to hunt you down like the rat that you are!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities